Yin Chen, Matchett Gerald
J Pain Palliat Care Pharmacother. 2014 Mar;28(1):33-6. doi: 10.3109/15360288.2013.876485. Epub 2014 Jan 29.
Inadequate pain relief from systemic medications is common in patients with advanced malignancy. Chest wall pain secondary to tumor involvement of chest wall structures can be challenging to manage with systemic medications, and occasionally patients benefit from interventional procedures such as intercostal nerve blocks and neurolysis. In this report, the authors describe the case of a 58-year-old woman with advanced non-small cell lung cancer with tumor invasion into the third thoracic rib. After reaching maximum tolerated doses of transdermal fentanyl, oral hydromorphone, and oral ketamine, the patient elected for intercostal nerve blockade and neurolysis. Prognostic nerve blockade was performed using liposomal bupivacaine administered via intercostal approach. This formulation of bupivacaine provided an excellent prognostic blockade, which lasted for approximately 96 hours. This extended period of time allowed the patient to fully evaluate the prognostic blockade, prior to proceeding with neurolysis with phenol. This case suggests that liposomal bupivacaine may be a valuable adjunctive agent for prognostic blockade prior to neurolysis for cancer pain.
对于晚期恶性肿瘤患者,全身用药止痛效果不佳很常见。胸壁结构受肿瘤侵犯继发的胸壁疼痛,使用全身用药治疗具有挑战性,偶尔患者可从肋间神经阻滞和神经溶解等介入治疗中获益。在本报告中,作者描述了一名58岁晚期非小细胞肺癌女性患者的病例,该患者肿瘤侵犯第三胸肋。在达到透皮芬太尼、口服氢吗啡酮和口服氯胺酮的最大耐受剂量后,患者选择进行肋间神经阻滞和神经溶解。采用经肋间途径给予脂质体布比卡因进行预后性神经阻滞。这种布比卡因制剂提供了出色的预后性阻滞,持续约96小时。这段延长的时间使患者能够在使用苯酚进行神经溶解之前充分评估预后性阻滞。该病例表明,脂质体布比卡因可能是癌症疼痛神经溶解术前预后性阻滞的一种有价值的辅助药物。